# 2025 Orphan Drugs: PDUFA Dates and FDA Approvals

By: [Peter Ciszewski](https://checkrare.com/author/peter-ciszewski/) \| Updated on: May 15, 2025

Below is the list of important regulatory dates for all orphan drugs for 2025.

Prescription Drug User Fee Act (PDUFA) dates refer to deadlines for the FDA to review new drugs.

| PDUFA Date | Orphan Drug | Indication | Company | Status |
| --- | --- | --- | --- | --- |
| [1.7.2025](https://www.globenewswire.com/en/news-release/2024/07/23/2917127/0/en/FDA-Accepts-Mesoblast-s-Biologics-License-Application-BLA-for-Ryoncil-in-Children-With-Steroid-Refractory-Acute-Graft-Versus-Host-Disease-SR-aGVHD.html). | Ryoncil (remestemcel) | Steroid-refractory acute graft versus host disease | Mesoblast Limited | [APPROVED](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-remestemcel-l-rknd-steroid-refractory-acute-graft-versus-host-disease-pediatric) |
| [1.15.2025](https://investors.atarabio.com/news-events/press-releases/detail/356/atara-biotherapeutics-announces-u-s-fda-acceptance-and) | Tabelecleucel (Tab-cel) | Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease | Atara Biotherapeutics | [Complete Response Letter](https://checkrare.com/efficacy-of-tabelecleucel-to-treat-ebstein-barr-virus-positive-post-transplant-lymphoproliferative-disease/) |
| [2.17.2025﻿](https://finance.yahoo.com/news/fda-accepts-deciphera-vimseltinib-nda-103317199.html?guccounter=1&guce_referrer=aHR0cHM6Ly93d3cuZ29vZ2xlLmNvbS8&guce_referrer_sig=AQAAAGVKZr6VRGDCzZ6bdfMA_VktJtX_zZwm-j288worb4FuS-qZFvu2mRIiWtzdHsvMLuDBBh2VVRT1FHtiRDiiJtlyGhD6ebOUyih8hzxSf0nL8AIyu9rvORHDu_Bqx6iG5HcArpBEKl7c_gvTlgbXlYJ4kvtmGku--2AluRRwpB9p) | Vimseltinib | Tenosynovial giant cell tumor (TGCT) | Deciphera Pharmaceuticals | [APPROVED](https://checkrare.com/fda-approves-vimseltinib-for-tenosynovial-giant-cell-tumor/) |
| [2.21.2025](https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-cerebrotendinous-xanthomatosis-rare-lipid-storage-disease) | Ctexli (chenodiol) | Cerebrotendinous xanthomatosis | Mirum Therapeutics | [APPROVED](https://checkrare.com/fda-approves-first-treatment-for-cerebrotendinous-xanthomatosis/) |
| [2.28.2025﻿](https://www.globenewswire.com/en/news-release/2024/08/28/2936845/0/en/FDA-Grants-Priority-Review-to-SpringWorks-Therapeutics-New-Drug-Application-for-Mirdametinib-for-the-Treatment-of-Adults-and-Children-with-NF1-PN.html) | Mirdametinib | Neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN) | Springworks Therapeutics | [APPROVED](https://checkrare.com/fda-approves-mirdametinib-for-treatment-of-nf1-pn/) |
| [3.6.2025](https://www.neurotechpharmaceuticals.com/wp-content/uploads/Neurotech_Press-Release_BLA_Approval_FINAL.pdf) | Encelto (revakinagene taroretcel-lwey) | Macular telangiectasia type 2 (MacTel) | Neurotech Pharmaceuticals | [APPROVED](https://checkrare.com/fda-approves-first-treatment-for-macular-telangiectasia-type-2/) |
| [3.20.2025](https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-first-treatment-adults-complement-3-glomerulopathy-rare-kidney-disease-reduce) | Fabhalta (iptacopan) | C3 glomerulopathy (C3G) | Novartis | [APPROVED](https://checkrare.com/fda-approves-first-treatment-for-c3-glomerulopathy/) |
| [3.20.2025](https://www.onclive.com/view/fda-accepts-nda-resubmission-for-first-line-rivoceranib-camrelizumab-combo-in-unresectable-hcc) | Rivoceranib/Camrelizumab | Unresectable or metastatic hepatocellular carcinoma | Elevar Therapeutics | [Complete Response Letter](https://checkrare.com/complete-response-letter-issued-for-hepatocellular-carcinoma-combination-therapy/) |
| [3.23.2025](https://investors.alnylam.com/press-release?id=28546) | Vutrisiran | ATTR-CM | Alnylam Pharmaceuticals | [APPROVED](https://checkrare.com/fda-approves-first-treatment-for-transthyretin-amyloid-cardiomyopathy/) |
| [3.27.2025](https://investors.soleno.life/news-releases/news-release-details/soleno-therapeutics-announces-fda-extension-review-period-dccr) | Diazoxide choline (DCCR) | Prader-Willi syndrome | Soleno Therapeutics | [APPROVED](https://checkrare.com/fda-approves-therapy-for-prader-willi-syndrome/) |
| [3.28.2025](https://www.sanofi.com/en/media-room/press-releases/2024/2024-06-21-05-00-00-2902104) | Fitusiran | Hemophilia A or B | Sanofi | [APPROVED](https://checkrare.com/fda-approves-fitusiran-for-treatment-of-hemophilia-a-and-b/) |
| [4.2.2025](https://www.novartis.com/us-en/news/media-releases/novartis-receives-fda-accelerated-approval-vanrafia-atrasentan-first-and-only-selective-endothelin-receptor-antagonist-proteinuria-reduction-primary-iga-nephropathy-igan) | Vanrafia (atrasentan) | IgA nephropathy | Novartis | [APPROVED](https://checkrare.com/approval-of-eta-receptor-for-treatment-of-adults-with-iga-nephropathy/) |
| [4.3.2025](https://www.sec.gov/Archives/edgar/data/318154/000031815425000005/amgn-20241231earningsrelea.htm) | Uplizna (inebilizumab) | Immunoglobulin G4-related disease (IgG4-RD) | Amgen | [APPROVED](https://checkrare.com/fda-approves-the-first-treatment-for-immunoglobulin-g4-related-disease/) |
| [4.21.2025](https://www.businesswire.com/news/home/20240820020926/en/Bristol-Myers-Squibb-Receives-U.S.-Food-and-Drug-Administration-sBLA-Acceptance-for-First-Line-Treatment-of-Unresectable-Hepatocellular-Carcinoma) | Nivolumab plus ipilimumab | Hepatocellular carcinoma (HCC) | Bristol Myers Squibb | [APPROVED](https://checkrare.com/fda-approves-hepatocellular-carcinoma-combination-therapy/) |
| [4.29.2025﻿](https://investors.abeonatherapeutics.com/press-releases/detail/294/abeona-therapeutics-announces-fda-acceptance-of-bla) | Prademagene zamikeracel (pz-cel) | Epidermolysis bullosa | Abeona Therapeutics | [APPROVED](https://checkrare.com/fda-approves-gene-therapy-for-epidermolysis-bullosa-2/) |
| [4.29.2025](https://www.prnewswire.com/news-releases/stealth-biotherapeutics-announces-pdufa-action-date-extension-for-elamipretide-to-treat-patients-with-barth-syndrome-302358052.html) | Elamipretide | Barth syndrome | Stealth BioTherapeutics | [Delayed](https://stealthbt.com/stealth-biotherapeutics-announces-delay-in-fda-action-date-for-barth-syndrome-application/) |
| [4.30.2025](https://www.multivu.com/johnson-johnson/9331651-en-johnson-johnson-receives-fda-approval-imaavy-nipocalimab-aahu) | Nipocalimab | Generalized myasthenia gravis | Johnson & Johnson | [APPROVED](https://checkrare.com/fda-approves-myasthenia-gravis-treatment-nipocalimab/) |
| [5.24.2025](https://www.liquidia.com/news-releases/news-release-details/liquidia-corporation-announces-fda-acceptance-new-drug#:~:text=The%20FDA%20confirmed%20that%20the,Dr.) | Yutrepia (treprostinil) | Pulmonary arterial hypertension | Liquidia Corporation | [APPROVED](https://checkrare.com/fda-approves-inhalation-powder-formulation-of-treprostinil-for-pulmonary-arterial-hypertension/) |
| [5.26.2025](https://www.businesswire.com/news/home/20250127087005/en/FDA-Grants-Priority-Review-to-Mercks-Application-for-WELIREG-belzutifan-for-the-Treatment-of-Patients-With-Advanced-Pheochromocytoma-and-Paraganglioma-PPGL) | Welireg (belzutifan) | Advanced pheochromocytoma and paraganglioma (PPGL) | Merck | [APPROVED](https://checkrare.com/fda-approves-treatment-for-pheochromocytoma-or-paraganglioma/) |
| [5.28.2025](https://ir.etonpharma.com/news-releases/news-release-details/eton-pharmaceuticals-announces-extension-pdufa-goal-date-et-400) | Khindivi (hydrocortisone) | Pediatric adrenal insufficiency | Eton Pharmaceuticals | [APPROVED](https://checkrare.com/fda-approves-new-formulation-of-treatment-for-adrenal-insufficiency/) |
| [6.17.2025](https://ir.kalvista.com/news-releases/news-release-details/kalvista-announces-fda-acceptance-new-drug-application) | Sebetralstat | Hereditary angioedema | KalVista Pharmaceuticals | [PDUFA Delayed](https://ir.kalvista.com/news-releases/news-release-details/kalvista-pharmaceuticals-announces-fda-will-not-meet-pdufa-goal) |
| [6.18.2025](https://www.prnewswire.com/news-releases/us-food-and-drug-administration-approves-csls-andembry-garadacimab-gxii-the-only-prophylactic-hereditary-angioedema-hae-treatment-targeting-factor-xiia-with-once-monthly-dosing-for-all-patients-from-the-start-302483058.html) | Andembry (garadacimab) | Hereditary angioedema | CSL | [APPROVED](https://checkrare.com/fda-approves-garadacimab-for-hereditary-angioedema/) |
| [6.19.2025](https://www.biospace.com/fda/cycle-wins-first-fda-nod-for-ultra-rare-genetic-disease) | Nitisinone | Alkaptonuria | Cycle Pharmaceuticals | [APPROVED](https://checkrare.com/fda-approves-nitisinone-for-the-treatment-of-alkaptonuria/) |
| [6.20.2025](https://www.sanofi.com/en/media-room/press-releases/2025/2025-02-18-06-00-00-3027482) | Dupixent | Bullous Pemphigoid | Sanofi | [APPROVED](https://checkrare.com/fda-approves-dupixent-for-the-treatment-of-bullous-pemphigoid/) |
| [6.23.2025](https://www.businesswire.com/news/home/20241223905597/en/U.S.-Food-and-Drug-Administration-Accepts-for-Priority-Review-Nuvation-Bio%E2%80%99s-New-Drug-Application-for-Taletrectinib-for-the-Treatment-of-Advanced-ROS1-positive-Non-Small-Cell-Lung-Cancer) | Taletrectinib | Advanced ROS1-positive non-small cell lung cancer | Nuvation Bio | [APPROVED](https://checkrare.com/fda-approves-taletrectinib-for-rare-form-of-lung-cancer/) |
| [6.28.2025](https://www.sobi.com/en/press-releases/fda-approves-gamifantr-emapalumab-lzsg-first-ever-treatment-adults-and-children-macrophage-activation-syndrome-stills-disease-2342991) | Gamifant (emapalumab) | Still's disease | Sobi | [APPROVED](https://checkrare.com/fda-approves-emapalumab-to-treat-stills-disease/) |
| [6.30.2025](https://www.takeda.com/newsroom/newsreleases/2025/gammagard-immunoglobulin/) | Gammagard Liquid ERC (immune globulin infusion) | Primary immunodeficiencies | Takeda | [APPROVED](https://checkrare.com/fda-approves-therapy-for-primary-immunodeficiencies/) |
| [7.10.2025](https://investor.regeneron.com/news-releases/news-release-details/linvoseltamab-bla-accepted-fda-review-treatment) | Linvoseltamab | Multiple myeloma | Regeneron Pharmaceuticals | [APPROVED](https://checkrare.com/fda-approves-linvoseltamab-for-treatment-of-multiple-myeloma/) |
| [7.24.2025﻿](https://www.biospace.com/press-releases/sobi-announces-fda-acceptance-of-new-drug-application-for-avatrombopag-doptelet-for-the-treatment-of-pediatric-immune-thrombocytopenia) | Avatrombopag | Immune thrombocytopenia | Sobi North America | [APPROVED](https://checkrare.com/the-fda-approves-avatrombopag-to-treat-young-children-with-itp/) |
| [7.27.2025](https://investors.ascendispharma.com/news-releases/news-release-details/fda-accepts-ascendis-pharmas-supplemental-biologics-license) | TransCon hGH | Growth hormone deficiency | Ascendis Pharma | [APPROVED](https://checkrare.com/fda-approves-lonapegsomatropin-for-treatment-of-adults-with-growth-hormone-deficiency/) |
| [7.28.2025](https://investors.apellis.com/news-releases/news-release-details/apellis-announces-fda-acceptance-and-priority-review) | Empaveli (pegcetacoplan) | C3G and primary IC-MPGN | Apellis Pharmaceuticals | [APPROVED](https://checkrare.com/the-fda-approves-pegcetacoplan-for-treatment-of-rare-kidney-disorders-c3g-and-ic-mpgn/) |
| [7.29.2025](https://ir.ptcbio.com/news-releases/news-release-details/ptc-therapeutics-announces-fda-target-regulatory-action-date) | Sepiapterin | Phenylketonuria (PKU) | PTC Therapeutics | [APPROVED](https://checkrare.com/the-fda-approves-sepiapterin-for-treatment-of-phenylketonuria/) |
| [7.30.2025](https://investor.regeneron.com/news-releases/news-release-details/odronextamab-bla-accepted-fda-review-treatment) | Odronextamab | Follicular lymphoma | Regeneron Pharmaceuticals | [Complete Response Letter](https://investor.regeneron.com/news-releases/news-release-details/regeneron-reports-second-quarter-2025-financial-and-operating) |
| [7.31.2025](https://www.novonordisk-us.com/media/news-archive/news-details.html?id=916409) | Alhemo (concizumab) | Hemophilia A or B without inhibitors | Novo Nordisk | [APPROVED](https://checkrare.com/fda-approves-concizumab-for-hemophilia-a-or-b-without-inhibitors/) |
| [8.18.2025](https://ir.ultragenyx.com/news-releases/news-release-details/ultragenyx-announces-fda-acceptance-and-priority-review) | UX111 | Sanfilippo syndrome (MPS IIIA) | Ultragenyx | [Complete Response Letter](https://ir.ultragenyx.com/news-releases/news-release-details/ultragenyx-receives-complete-response-letter-fda-ux111-aav-gene) |
| [8.18.2025](https://www.globenewswire.com/news-release/2025/02/18/3027655/25619/en/Chimerix-Announces-FDA-Acceptance-and-Priority-Review-of-New-Drug-Application-for-Dordaviprone-as-Treatment-for-Recurrent-H3-K27M-Mutant-Diffuse-Glioma.html) | Dordaviprone | H3 K27M-mutant diffuse glioma | Jazz Pharmaceuticals | [APPROVED](https://checkrare.com/fda-approves-dordaviprone-for-rare-type-of-glioma/) |
| [8.19.2025](https://ir.ptcbio.com/news-releases/news-release-details/ptc-therapeutics-announces-fda-acceptance-and-priority-review-0) | Vatiquinone | Friedreich's ataxia | PTC Therapeutics | [Complete Response Letter](https://ir.ptcbio.com/news-releases/news-release-details/ptc-therapeutics-receives-complete-response-letter-vatiquinone) |
| [8.21.2025﻿](https://www.prnewswire.com/news-releases/ionis-announces-fda-acceptance-of-new-drug-application-for-donidalorsen-for-prophylactic-treatment-of-hae-302295444.html) | Donidalorsen | Hereditary Angioedema | Ionis Pharmaceuticals | [APPROVED](https://checkrare.com/fda-approves-donidalorsen-for-treatment-of-hereditary-angioedema-hae/) |
| [8.27.2025](https://www.prnewswire.com/news-releases/fda-grants-priority-review-to-precigens-bla-for-prgn-2012-for-the-treatment-of-adults-with-recurrent-respiratory-papillomatosis-with-pdufa-target-action-date-set-for-august-27-2025-302384347.html) | PRGN-2012 (zopapogene imadenovec) | Recurrent respiratory papillomatosis (RRP) | Precigen | [APPROVED](https://checkrare.com/fda-approves-papzimeos-zopapogene-imadenovec-for-recurrent-respiratory-papillomatosis/) |
| [8.28.2025](https://ir.travere.com/news-releases/news-release-details/travere-therapeutics-provides-corporate-update-and-2025-outlook) | Filspari | IgA nephropathy | Travere Therapeutics | [APPROVED](https://checkrare.com/fda-approves-updated-rems-for-iga-nephropathy-treatment/) |
| [8.29.2025](https://www.sanofi.com/en/media-room/press-releases/2024/2024-12-07-16-30-00-2993342) | Rilzabrutinib | Immune thrombocytopenia | Sanofi | [APPROVED](https://checkrare.com/fda-approves-sanofis-rilzabrutinib-for-treatment-of-patients-with-chronic-itp/) |
| [8.31.2025](https://www.capricor.com/investors/news-events/press-releases/detail/305/capricor-therapeutics-announces-fda-acceptance-and-priority) | Deramiocel | Duchenne muscular dystrophy | Capricor Therapeutics | [Complete Response Letter](https://www.capricor.com/investors/news-events/press-releases/detail/319/capricor-therapeutics-provides-regulatory-update-on) |
| [9.12.2025](https://ir.biocryst.com/news-releases/news-release-details/biocryst-announces-fda-acceptance-nda-orladeyor-berotralstat) | Orladeyo (berotralstat) | Hereditary angioedema (HAE) | BioCryst Pharmaceuticals | NDA accepted |
| [9.22.2025](https://investors.scholarrock.com/news-releases/news-release-details/fda-grants-priority-review-biologics-license-application-bla-and) | Apitegromab | Spinal muscular atrophy | Scholar Rock | BLA accepted |
| [9.25.2025](https://www.biospace.com/press-releases/crinetics-announces-fda-acceptance-of-new-drug-application-for-paltusotine-for-adult-patients-with-acromegaly) | Paltusotine | Acromegaly | Crinetics Pharmaceuticals | NDA accepted |
| [9.30.2025](https://www.fortressbiotech.com/news-media/press-releases/detail/681/fortress-biotech-and-cyprium-therapeutics-announce-u-s-fda) | CUTX-101 (Copper Histidinate) | Menkes disease | Fortress Biotech | NDA accepted |
| [10.20.2025](https://investors.glaukos.com/investors/news/news-details/2025/Glaukos-Announces-FDA-Acceptance-of-NDA-Submission-for-Epioxa/default.aspx) | Epioxa (Epi-on) | Keratoconus | Glaukos Corporation | NDA accepted |
| [10.23.2025](https://us.gsk.com/en-us/media/press-releases/gsk-announces-extension-of-us-food-and-drug-administration-review-period-for-blenrep-belantamab-mafodotin-blmf-in-relapsedrefractory-multiple-myeloma/) | Belantamab mafodotin | Multiple myeloma | GSK | BLA accepted |
| [10.25.2025](https://ir.syndax.com/news-releases/news-release-details/syndax-announces-fda-priority-review-snda-revuforjr-revumenib) | Revuforj (revumenib) | mNPM1 acute myeloid leukemia | Syndax Pharmaceuticals | sNDA accepted |
| [11.18.2025](https://ir.arrowheadpharma.com/news-releases/news-release-details/arrowhead-pharmaceuticals-announces-acceptance-new-drug) | Plozasiran | Familial chylomicronemia syndrome | Arrowhead Pharmaceuticals | NDA accepted |
| [11.28.2025](https://www.otsuka-us.com/news/otsuka-files-biologics-license-application-bla-sibeprenlimab-treatment-immunoglobulin) | Sibeprenlimab | Immunoglobulin A nephropathy (IgAN) | Otsuka Pharmaceutical Co. | BLA accepted |
| [11.30.2025](https://www.globenewswire.com/news-release/2025/06/01/3091510/0/en/Kura-Oncology-and-Kyowa-Kirin-Announce-FDA-Acceptance-and-Priority-Review-of-New-Drug-Application-for-Ziftomenib-in-Adults-with-Relapsed-or-Refractory-NPM1-Mutant-AML.html) | Ziftomenib | Relapsed or refractory acute myeloid leukemia (AML) with an NPM1 mutation | Kura Oncology and Kyowa Kirin | NDA accepted |
| [12.7.2025](https://investor.agios.com/news-releases/news-release-details/agios-provides-update-us-pdufa-goal-date-pyrukyndr-mitapivat) | Pyrukynd (mitapivat) | Alpha- and beta-thalassemia | Agios Pharmaceuticals | sNDA accepted |
| 12.14.2025 | Uplizna | Myasthenia gravis | Amgen | Regulatory submission accepted |
| [12.26.2025](https://ir.cytokinetics.com/news-releases/news-release-details/cytokinetics-announces-new-pdufa-date-aficamten-obstructive) | Aficamten | Obstructive hypertrophic cardiomyopathy (oHCM) | Cytokinetics | NDA accepted |
| [12.30.2025](https://www.biospace.com/press-releases/fda-files-corcepts-new-drug-application-for-relacorilant-as-treatment-for-patients-with-hypercortisolism) | Relacorilant | Cushing's syndrome | Corcept Therapeutics | NDA accepted |
| [Q4 2025](https://ir.biohaven.com/news-releases/news-release-details/fda-extends-pdufa-date-biohavens-troriluzole-nda-rare-disease) | Troriluzole | Spinocerebellar ataxia (SCA) | Biohaven | NDA accepted |
| [1.5.2026](https://www.biospace.com/press-releases/denali-therapeutics-announces-fda-acceptance-and-priority-review-of-biologics-license-application-bla-for-tividenofusp-alfa-for-hunter-syndrome-mps-ii) | Tividenofusp alfa | Hunter syndrome (MPS II) | Denali Therapeutics | BLA accepted |
| [2.8.2026](https://ir.regenxbio.com/news-releases/news-release-details/regenxbio-announces-fda-acceptance-and-priority-review-bla-rgx) | Clemidsogene lanparvovec (RGX-121) | Mucopolysaccharidosis II (MPS II) | REGENXBIO | BLA accepted |
| [10.10.2026](https://www.biospace.com/press-releases/pierre-fabre-pharmaceuticals-inc-announces-fda-acceptance-and-priority-review-of-the-biologics-license-application-bla-for-tabelecleucel-for-the-treatment-of-epstein-barr-virus-positive-post-transplant-lymphoproliferative-disease-ebv-ptld) | Tabelecleucel | Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD) | Pierre Fabre Pharmaceuticals | BLA accepted |
| [2.25.2026](https://www.cancernetwork.com/view/fda-accepts-snda-for-decitabine-cedazuridine-combo-in-newly-diagnosed-aml) | Inqovi (decitabine and cedazuridine) plus Venclexta (venetoclax) | Acute myeloid leukemia | Taiho Oncology | sNDA accepted |

> [**2024 Orphan Drugs: PDUFA Dates and FDA Approvals**](https://checkrare.com/2024-orphan-drugs-pdufa-dates-and-fda-approvals-2/)

> ##### **[2023 Orphan Drugs: PDUFA Dates and FDA Approvals](https://checkrare.com/2023-orphan-drugs-pdufa-dates-and-fda-approvals/)**

> ##### **[2022 Orphan Drugs: PDUFA Dates and FDA Approvals](https://checkrare.com/2022-orphan-drugs-pdufa-dates-and-fda-approvals/)**

> ##### **[2021 Orphan Drugs: PDUFA Dates and FDA Approvals](https://checkrare.com/2021-orphan-drugs-pdufa-dates-and-fda-approvals/)**

### Related Articles

- [How the Gene Therapy for Hemophilia B Got FDA…](https://checkrare.com/how-the-gene-therapy-for-hemophilia-b-got-fda-approval-the-hope-b-trial/)
- [FDA Approves Onivyde Combination for Metastatic…](https://checkrare.com/fda-approves-onivyde-combination-for-metastatic-pancreatic-cancer/)
- [FDA Approves Eohilia for Eosinophilic Esophagitis](https://checkrare.com/fda-approves-eohilia-for-eosinophilic-esophagitis/)
- [FDA Approves First CAR T-Cell Therapy for Adults…](https://checkrare.com/fda-approves-first-car-t-cell-therapy-for-adults-with-leukemia-or-lymphoma/)
- [FDA Approves First-In-Class Treatment For Pulmonary…](https://checkrare.com/fda-approves-first-in-class-treatment-for-pulmonary-arterial-hypertension/)
- [FDA Approves Ultomiris for Treatment of…](https://checkrare.com/fda-approves-ultomiris-for-treatment-of-neuromyelitis-optica-spectrum-disorder-nmosd/)

- Login
- Sign Up

Remember me [Forgot Password?](https://checkrare.com/checkrare.com)

Sign in

I accept the [Terms of Service and Privacy Policy](https://checkrare.com/privacy-policy)

Sign Up

Lost your password? Please enter your username or email address. You will receive a link to create a new password via email.Email Reset Link

body::-webkit-scrollbar {
width: 7px;
}
body::-webkit-scrollbar-track {
border-radius: 10px;
background: #f0f0f0;
}
body::-webkit-scrollbar-thumb {
border-radius: 50px;
background: #dfdbdb
}

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.

Do not sell my personal information.

Cookie SettingsAccept

Manage consent

Close

#### Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.

Necessary

Necessary

Always Enabled

Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.

| Cookie | Duration | Description |
| --- | --- | --- |
| cookielawinfo-checkbox-analytics | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics". |
| cookielawinfo-checkbox-functional | 11 months | The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional". |
| cookielawinfo-checkbox-necessary | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary". |
| cookielawinfo-checkbox-others | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other. |
| cookielawinfo-checkbox-performance | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance". |
| viewed\_cookie\_policy | 11 months | The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data. |

Functional

functional

Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.

Performance

performance

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

Analytics

analytics

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.

Advertisement

advertisement

Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.

Others

others

Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.

Save & Accept